Advertisement

Osteoporosemittel

  • Ulrich Schwabe
  • Reinhard Ziegler

Zusammenfassung

Hauptvertreter der Osteoporosemittel sind Bisphosphonate, die in der Onkologie auch dem Schutz vor Knochenmetastasen dienen. Seit 3 Jahren zeichnet sich ein Rückgang der Bisphosphonatverordnungen ab. Leitsubstanz der Bisphosphonate ist Alendronsäure, auf die jetzt 70% des Verordnungsvolumens dieser Stoffgruppe entfallen, während Risedronsäure (13%) und Ibandronsäure (11%) deutlich kleinere Anteile haben. Mit weitem Abstand folgen Raloxifen und Strontiumranelat sowie weiterhin kräftig aufsteigend Denosumab. Fluoridpräparate sind unverändert rückläufig.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Arzneimittelkommission der Deutschen Ärzteschaft (2008): Empfehlungen zur Therapie und Prophylaxe der Osteoporose. Arzneiverordnung in der Praxis (Sonderheft 34S), 2. Auflage. Im Internet: www.akdae.de/35/83_Osteoporose_2008_2Auflage.pdf
  2. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG (2004) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350:1516–1525PubMedCrossRefGoogle Scholar
  3. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM (2007) Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 71:438–441PubMedCrossRefGoogle Scholar
  4. Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD, Reid IR (2010) Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: metaanalysis. BMJ 341:c369–1Google Scholar
  5. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA; Alendronate Phase III Osteoporosis Treatment Study Group (2004) Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189–1199CrossRefGoogle Scholar
  6. Brancaccio D, Cozzolino M (2007) Lanthanum carbonate: time to abandon prejudices? Kidney Int 71:190–192PubMedCrossRefGoogle Scholar
  7. Brown JE, Coleman RE (2012) Denosumab in patients with cancer-a surgical strike against the osteoclast. Nat Rev Clin Oncol 9:110–118PubMedCrossRefGoogle Scholar
  8. Compston J (2009) Recent advances in the management of osteoporosis. Clin Med 9:565–569PubMedCrossRefGoogle Scholar
  9. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C; FREEDOM Trial (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765PubMedCrossRefGoogle Scholar
  10. Dachverband O (2009) DVO-Leitlinie 2009 zur Prophylaxe, Diagnostik und Therapie der Osteoporose bei Erwachsenen. Langfassung Osteologie 18:304–324Google Scholar
  11. Drüeke TB (2007) Lanthanum carbonate as a first-line phosphate binder: the „cons”. Semin Dial 20:329–332PubMedCrossRefGoogle Scholar
  12. Ensrud KE, Stock JL, Barrett-Connor E, Grady D, Mosca L, Khaw KT, Zhao Q, Agnusdei D, Cauley JA (2008) Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial. J Bone Miner Res 23:112–120PubMedCrossRefGoogle Scholar
  13. Favia G, Pilolli GP, Maiorano E (2009) Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: an analysis of 31 cases with confocal laser scanning microscopy. Bone 45:406–413PubMedCrossRefGoogle Scholar
  14. Food andDAdministration (2013): FDA Drug Safety Communication: Pediatric clinical studies of Sensipar (cinacalcet hydrochloride) suspended after report of death. Internet: http://www.fda.gov/Drugs/DrugSafety/ucm340551.htm
  15. Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE et al.; Women's Health Initiative Investigators (2006): Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 354: 669–683Google Scholar
  16. Lamy O (2012) Knochenanabole Therapie mit Teriparatid. Ther Umsch 69:187–191PubMedCrossRefGoogle Scholar
  17. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JP, Pieger CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S; HORIZON Recurrent Fracture Trial (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1810PubMedCrossRefGoogle Scholar
  18. Manns B, Klarenbach S, Lee H, Culleton B, Shrive F, Tonelli M (2007) Economic evaluation of sevelamer in patients with end-stage renal disease. Nephrol Dial Transplant 22:2867–2878PubMedCrossRefGoogle Scholar
  19. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459–486PubMedCrossRefGoogle Scholar
  20. Consensus Conference NIH (1994): Optimal calcium intake. JAMA 272: 1942–1948Google Scholar
  21. Pazianas M, Compston J, Huang CL (2010) Atrial fibrillation and bisphosphonate therapy. J Bone Miner Res 25:2–10PubMedCrossRefGoogle Scholar
  22. Rachner TD, Khosla S, Hofbauer LC (2011) Osteoporosis: now and the future. The Lancet 377:1276–1287CrossRefGoogle Scholar
  23. Reginster JY, Bruyère O, Sawicki A, Roces-Varela A, Fardellone P, Roberts A, Devogelaer JP (2009) Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years. Bone 45:1059–1064PubMedCrossRefGoogle Scholar
  24. Rizzoli R, Boonen S, Brandi ML, Burlet N, Delmas P, Reginster JY (2008) The role of calcium and vitamin D in the management of osteoporosis. Bone 42:246–249PubMedCrossRefGoogle Scholar
  25. Sainz M, del Pozo JG, Arias LH, Carvajal A (2009) Strontium ranelate may cause alopecia. BMJ 338:1494–1498CrossRefGoogle Scholar
  26. Seeman E, Devogelaer J-P, Lorenc R, Spector T, Brixeu K, Balogh A, Stucki G, Reginster JY (2008) Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia. J Bone Miner Res 23:433–438PubMedCrossRefGoogle Scholar
  27. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O’Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M; American Society for Bone and Mineral Research (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25:2267–2294PubMedCrossRefGoogle Scholar
  28. Silverberg SJ, Fairman C, Bilezikian JP et al. (2004): Cinacalcet HCl effectively treats hypercalcemia in patients with parathyroid carcinoma (abstract no. SA495). J Bone Miner Res 19 Suppl. 1: S103Google Scholar
  29. Straub DA (2007) Calcium supplementation in clinical practice: a review of forms, doses, and indications. Nutr Clin Pract 22:286–296PubMedCrossRefGoogle Scholar
  30. Suki W, Zabaneh R, CangianoJ, Reed J, Fischer D, Garrett L, Ling B, Chasan-Taber S, Dillon M, Blair A, Burke S (2006) A prospective, randomized trial assessing the impact on outcomes of sevelamer in dialysis patients. The DCOR trial. Nephrol Dial Transplant 21(Suppl 4):145–146Google Scholar
  31. Wade SW, Curtis JR, Yu J, White J, Stolshek BS, Merinar C, Balasubramanian A, Kallich JD, Adams JL, Viswanathan HN (2012) Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan. Bone 50:870–875PubMedCrossRefGoogle Scholar
  32. Ziegler R (2002) Osteoporose: aktuelle Diagnostik und Therapie. Orthopädische Praxis 38:570–577Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Ulrich Schwabe
    • 1
  • Reinhard Ziegler
    • 2
  1. 1.Pharmakologisches InstitutUniversität HeidelbergHeidelberg
  2. 2.Heidelberg

Personalised recommendations